DBV Technologies Reports December 31, 2016 Cash Position
(Thomson Reuters ONE) -
Press Release
Montrouge, France, February 20, 2017
DBV Technologies Reports December 31, 2016 Cash Position
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), today announced its cash and cash equivalents as of December 31, 2016.
Full year 2016 financial results will be announced on March 15, 2017.
Cash and cash equivalents
DBV's cash and cash equivalents amounted to ?256.5 million as of December
31, 2016, compared to ?323.4 million as of December 31, 2015.
Number of outstanding and fully diluted shares
As of December 31, 2016, DBV's number of outstanding shares was 24,648,828
ordinary shares and on a fully diluted basis[i], the number of shares was
27,255,263.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY.
Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN
code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global
Select Market in the form of American Depositary Shares (each representing one-
half of one ordinary share) (Ticker: DBVT). For more information on DBV
Technologies, please visit our website: www.dbv-technologies.com
Forward Looking Statements
This press release may contain forward-looking statements and estimates. These
forward-looking statements and estimates are not promises or guarantees and
involve substantial risks and uncertainties. At this stage, the products of the
Company have not been authorized for sale in any country. Among the factors that
could cause actual results to differ materially from those described or
projected herein include uncertainties associated generally with research and
development, clinical trials and related regulatory reviews and approvals, the
risk that historical preclinical results may not be predictive of future
clinical trial results, and the risk that historical clinical trial results may
not be predictive of future trial results. A further list and description of
these risks, uncertainties and other risks can be found in the Company's
regulatory filings with the French Autorité des Marchés Financiers, the
Company's Securities and Exchange Commission filings and reports, including in
the Company's Annual Report on Form 20-F for the year ended December 31, 2015
and future filings and reports by the Company. Existing and prospective
investors are cautioned not to place undue reliance on these forward-looking
statements and estimates, which speak only as of the date hereof. Other than as
required by applicable law, DBV Technologies undertakes no obligation to update
or revise the information contained in this Press Release.
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
afassacesia(at)webershandwick.com
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
--------------------------------------------------------------------------------
[i] fully diluted share capital represents all issued and outstanding shares, as
well as all potential shares which may be issued upon exercise of outstanding
employee warrants, employee free shares and share options and nonemployee
warrants, as approved by DBV Technologies shareholders and granted by the board
of directors.
PDF Version:
http://hugin.info/156437/R/2079730/783141.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.02.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 525125
Anzahl Zeichen: 5291
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 329 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Reports December 31, 2016 Cash Position"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
